Cameron Turtle, Spyre Therapeutics CEO

Fresh from re­brand, Spyre Ther­a­peu­tics rais­es $180M as it steers TLA1 pro­gram to clin­ic

Spyre Ther­a­peu­tics is pulling in $180 mil­lion in a pri­vate place­ment just a cou­ple of weeks af­ter it re­brand­ed from Ae­glea …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.